To access this material please log in or register

Register Authorize

The clinical significance of copeptin and matrix metalloproteinases in men with acute coronary syndrome

Tanana O. S.1, Sukmanova I. A.2, Ponomarenko I. V.1
1 – Altai regional cardiological dispensary, Malakhov street 46, Barnaul, Altai Territory 656055
2 – Altai State Medical University, Prospekt Lenina 40, Barnaul, Altai Territory 656038

Keywords: copeptin, matrix metalloproteinases, acute myocardial infarction

DOI: 10.18087/cardio.2400

Aim. To evaluate clinical value copeptin and matrix metalloproteinases in men with acute coronary syndrome (ACS). Materials and methods. The study included 152 men with ACS. After evaluation of the traditional markers of myocardial damage, the patients were divided into 2 groups: the first group included patients with myocardial infarction (MI) - 84 people, the average age was 56.6±1.0 years, the second - with unstable angina (UA) - 68 at the age of 61,4±1.2 years. All patients at admission and after 6 hours and on day 6 of hospitalization were evaluated for the level of CPK MB, troponin I, copeptin, MMP-1, MMP-2, MMP-7, MMP-9 and TIMP-1. Results. Concentration of copeptin at admission in patients with it is 3.5 times higher than in the group with UA and significantly higher than that of control group. To 6‑th day of hospitalization, the concentration of copeptin reduced, but nonetheless remains significantly higher than in the control group (0,9±0,1 vs. 0.2±0,0, p=0.000) without significant differences with group UA. The level of MMP-1 and MMP-2 in patients with MI and UA at admission higher than in the control group, and in case of MI these levels are significantly higher than in case of UA. Conclusion. The obtained data indicates the possibility of using copeptin as a marker of myocardial damage. Additionally, it indicates myocardial damage an increase in the level of MMP-1, MMP-2 and MMP-7
  1. O’Donoghue ML, Morrow DA, Cannon CP, Jarolim P, Desai NR, Sherwood MW et al. Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. J Am Heart Assoc. 2016;5 (5). DOI:10.1161/JAHA.115.002586.
  2. Sinning C, Ojeda F, Zeller T, Zengin E, Rupprecht H-J, Lackner K-J et al. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress. Can J Cardiol. 2016;32 (12):1470–7. DOI:10.1016/j.cjca.2016.05.010.
  3. Kip MM, Steuten LM, Koffijberg H, IJzerman MJ, Kusters R. Using expert elicitation to estimate the potential impact of improved diagnostic performance of laboratory tests: a case study on rapid discharge of suspected non-ST elevation myocardial infarction patients. J Eval Clin Pract. 2016; DOI:10.1111/jep.12626.
  4. Ahmad T, Wang T, O’Brien EC, Samsky MD, Pura JA, Lokhnygina Y et al. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. JACC Heart Fail. 2015;3 (1):30–9. DOI:10.1016/j.jchf.2014.06.013.
  5. Mueller M, Giannitsis E, Katus HA. [Essential cardiac biomarkers in myocardial infarction and heart failure]. Herz. 2014;39 (6):727–739; quiz 740–741. DOI:10.1007/s00059‑014‑4136‑8.
  6. Thelin J, Melander O, Öhlin B. Early rule-out of acute coronary syndrome using undetectable levels of high sensitivity troponin T. Eur Heart J Acute Cardiovasc Care. 2015;4 (5):403–9. DOI:10.1177/2048872614554107.
  7. Sörensen NA, Shah AS, Ojeda FM, Peitsmeyer P, Zeller T, Keller T et al. High-sensitivity troponin and novel biomarkers for the early diagnosis of non-ST-segment elevation myocardial infarction in patients with atrial fibrillation. Eur Heart J Acute Cardiovasc Care. 2016;5 (6):419–27. DOI:10.1177/2048872615611108.
  8. Vafaie M, Slagman A, Möckel M, Hamm C, Huber K, Müller C et al. Prognostic Value of Undetectable hs Troponin T in Suspected Acute Coronary Syndrome. Am J Med. 2016;129 (3):274–282.e2. DOI:10.1016/j.amjmed.2015.10.016.
  9. Smaradottir MI, Ritsinger V, Gyberg V, Norhammar A, Näsman P, Mellbin LG. Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities – A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diab Vasc Dis Res. 2017;14 (2):69–76. DOI:10.1177/1479164116664490.
  10. Tasevska I, Enhörning S, Persson M, Nilsson PM, Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart. 2016;102 (2):127–32. DOI:10.1136/heartjnl-2015–308183.
  11. Searle J, Slagman A, Stockburger M, Vollert JO, Müller C, Muller R et al. Use of copeptin in emergency patients with cardiac chief complaints. Eur Heart J Acute Cardiovasc Care. 2015;4 (5):393–402. DOI:10.1177/2048872614554197.
  12. Jacobs LHJ, van Borren M, Gemen E, van Eck M, van Son B, Glatz JFC et al. Rapidly rule out acute myocardial infarction by combining copeptin and heart-type fatty acid-binding protein with cardiac troponin. Ann Clin Biochem. 2015;52 (Pt 5):550–61. DOI:10.1177/0004563215578189.
  13. Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Adv Clin Chem. 2017;79:93–152. DOI:10.1016/bs.acc.2016.09.002.
  14. Stallone F, Schoenenberger AW, Puelacher C, Rubini Gimenez M, Walz B, Naduvilekoot Devasia A et al. Incremental value of copeptin in suspected acute myocardial infarction very early after symptom onset. Eur Heart J Acute Cardiovasc Care. 2016;5 (5):407–15. DOI:10.1177/2048872616641289.
  15. Hamed GM, Fattah MFA. Clinical Relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome. Clin Appl Thromb Hemost. 2015;21 (8):705–11. DOI:10.1177/1076029614567309.
Tanana O. S., Sukmanova I. A., Ponomarenko I. V. The clinical significance of copeptin and matrix metalloproteinases in men with acute coronary syndrome. Kardiologiia. 2017;57(S3):32–39

To access this material please log in or register

Register Authorize
Ru En